Description

HGH 191aa, formally known as Somatropin, is a laboratory-produced form of human growth hormone that is structurally identical to the hormone naturally secreted by the anterior pituitary gland. The term “191aa” refers to its structure of 191 amino acids, which precisely matches endogenous human growth hormone.

Somatropin is manufactured using recombinant DNA technology and is regulated as a prescription medication in many countries. It is approved for specific medical conditions involving growth hormone deficiency and related disorders.

Growth hormone is released in pulses throughout the day, with the largest pulses occurring during deep sleep. Once secreted into the bloodstream, it binds to growth hormone receptors in tissues throughout the body, particularly in the liver. This interaction stimulates the production of insulin-like growth factor 1 (IGF-1), which mediates many of growth hormone’s anabolic and tissue-building effects.

Its primary role is toward maintaining body composition, supporting muscle mass, regulating fat metabolism, preserving bone density, and contributing to tissue repair and recovery.

Somatropin therapy can increase lean body mass, reduce visceral fat, improve bone mineral density, enhance physical performance capacity, and improve overall quality of life. These effects occur primarily through increased IGF-1 signalling and enhanced protein synthesis.

HGH 191aa (somatropin) is a bio-identical recombinant form of human growth hormone used clinically to treat growth hormone deficiency and specific medical conditions. It plays a central role in growth, metabolism, and tissue repair through stimulation of IGF-1 production. While medically valuable when properly prescribed, its use outside of clinical supervision carries metabolic and systemic risks.

Click to access Protocols-3.pdf